Stock listing
R2AR34 Stock Price, News, Filings & Events — Ultragenyx Pharmaceutical Inc.
Selected listing: R2AR34 · BMFBOVESPA · BRL · BR
This page tracks Ultragenyx Pharmaceutical Inc.'s R2AR34:BMFBOVESPA listing on BMFBOVESPA in BRL for BR, including stock price context, company news, filings, investor events, AI research briefs, and market updates for investors following R2AR34:BMFBOVESPA. R2AR34:BMFBOVESPA is the stock-level entry point for investors researching Ultragenyx Pharmaceutical Inc., while company-level investor report content can remain shared across the same issuer's public listings. 6ix connects this selected listing to available company updates, filings, investor events, replay content, and AI research briefs so stock search leads to the relevant company context without making another exchange listing primary.
- Ticker
- R2AR34:BMFBOVESPA
- Asset type
- Stock
- Market cap
- $2.45B
- Sector
- Health Technology
- Industry
- Pharmaceuticals: Major
- Exchange
- BMFBOVESPA
- Currency
- BRL
Ultragenyx Pharmaceutical Inc. R2AR34:BMFBOVESPA stock context
This page tracks Ultragenyx Pharmaceutical Inc.'s R2AR34:BMFBOVESPA listing on BMFBOVESPA in BRL for BR, including stock price context, company news, filings, investor events, AI research briefs, and market updates for investors following R2AR34:BMFBOVESPA. R2AR34:BMFBOVESPA is the stock-level entry point for investors researching Ultragenyx Pharmaceutical Inc., while company-level investor report content can remain shared across the same issuer's public listings. 6ix connects this selected listing to available company updates, filings, investor events, replay content, and AI research briefs so stock search leads to the relevant company context without making another exchange listing primary.
Latest news from Ultragenyx Pharmaceutical Inc.
Ultragenyx Announces U.S. FDA Approval of GENGLYCOS Gene Therapy, the First-Ever FDA-Approved Treatment Designed to Treat the Underlying ...
August 20, 2026
Ultragenyx Announces U.S. FDA Approval of GENGLYCOS™ Gene Therapy, the First-Ever FDA-Approved Treatment Designed to Treat the Underlying...
August 19, 2026
Ultragenyx Reports Second Quarter 2026 Financial Results and Corporate Update
August 4, 2026
Ultragenyx to Host Conference Call for Second Quarter 2026 Financial Results and Corporate Update
July 28, 2026
Ultragenyx Releases 2025 Impact Report Emphasizing Commitment to Rare Disease Patients, Innovation, and Global Impact
July 8, 2026
Ultragenyx Pharmaceutical Inc. earnings calls
Ultragenyx Pharmaceutical Inc. (RARE) Q2 2026 Earnings Call
August 4, 2026 · Replay with transcript and chapters
Ultragenyx Pharmaceutical Inc. (RARE) Q1 2026 Earnings Call
May 5, 2026 · Replay with transcript and chapters
Ultragenyx Pharmaceutical Inc. (RARE) Q4 2025 Earnings Call
February 12, 2026 · Replay with transcript and chapters
Ultragenyx Pharmaceutical Inc. (RARE) Q3 2025 Earnings Call
November 4, 2025 · Replay with transcript and chapters
Ultragenyx Pharmaceutical Inc. (RARE) Q2 2025 Earnings Call
August 5, 2025 · Replay with transcript and chapters
Ultragenyx Pharmaceutical Inc. (RARE) Q1 2025 Earnings Call
May 6, 2025 · Replay with transcript and chapters
Research Ultragenyx Pharmaceutical Inc.
Ultragenyx Pharmaceutical Inc. investor report
Review AI stock analysis and investor report context for R2AR34:BMFBOVESPA.
Ultragenyx Pharmaceutical Inc. company profile
View the public company page for Ultragenyx Pharmaceutical Inc. on 6ix.
Ultragenyx Pharmaceutical Inc. news
Read company news and market updates connected to Ultragenyx Pharmaceutical Inc..
Ultragenyx Pharmaceutical Inc. investor events
Find investor webinars, events, and replay context for Ultragenyx Pharmaceutical Inc..
Alternate listings
RARE:NASDAQ
US · USD
Alternate listing for Ultragenyx Pharmaceutical Inc.; the primary context on this page is R2AR34:BMFBOVESPA.
0LIF:LSE
GB · USD
Alternate listing for Ultragenyx Pharmaceutical Inc.; the primary context on this page is R2AR34:BMFBOVESPA.
UP0:GETTEX
DE · EUR
Alternate listing for Ultragenyx Pharmaceutical Inc.; the primary context on this page is R2AR34:BMFBOVESPA.
RARE:BMV
MX · MXN
Alternate listing for Ultragenyx Pharmaceutical Inc.; the primary context on this page is R2AR34:BMFBOVESPA.
A1XCY0:LSX
DE · EUR
Alternate listing for Ultragenyx Pharmaceutical Inc.; the primary context on this page is R2AR34:BMFBOVESPA.
A1XCY0:LS
DE · EUR
Alternate listing for Ultragenyx Pharmaceutical Inc.; the primary context on this page is R2AR34:BMFBOVESPA.
RARE:BIVA
MX · MXN
Alternate listing for Ultragenyx Pharmaceutical Inc.; the primary context on this page is R2AR34:BMFBOVESPA.
UP0:FWB
DE · EUR
Alternate listing for Ultragenyx Pharmaceutical Inc.; the primary context on this page is R2AR34:BMFBOVESPA.
UP0:TRADEGATE
DE · EUR
Alternate listing for Ultragenyx Pharmaceutical Inc.; the primary context on this page is R2AR34:BMFBOVESPA.
RARE:BOATS
US · USD
Alternate listing for Ultragenyx Pharmaceutical Inc.; the primary context on this page is R2AR34:BMFBOVESPA.
UP0:BX
CH · CHF
Alternate listing for Ultragenyx Pharmaceutical Inc.; the primary context on this page is R2AR34:BMFBOVESPA.
UP0:DUS
DE · EUR
Alternate listing for Ultragenyx Pharmaceutical Inc.; the primary context on this page is R2AR34:BMFBOVESPA.